Prev: Methodology of Testing for Antinuclear Antibodies (ACR Position Statement)Next: Identifying antinuclear antibody positive individuals at risk for developing systemic autoimmune disease: development and validation of a real-time risk model
Record 053 · Clinical guidance · 2024
Advisory Panel Guidance on Minimum Retesting Intervals for Lab Tests
Canadian Agency for Drugs and Technologies in Health · requested inclusion
“Advisory panel guidance recommends against repeating a prior positive ANA solely to monitor suspected or confirmed systemic autoimmune disease; new symptoms can justify reassessment after a negative or borderline result.”
Advisory panel guidance recommends against repeating a prior positive ANA solely to monitor suspected or confirmed systemic autoimmune disease; new symptoms can justify reassessment after a negative or borderline result. Limits noted in the record: The guidance covers repeat ANA testing, not initial diagnosis. A positive ANA is not a diagnosis. Claims in this record are not verified.
A positive ANA is not a diagnosis. Claims in this record are not verified.
source
- repeat-testing
- change-over-time
Clinical guidance
Also in this file
View all in file
2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus19.01.X · Annals of the Rheumatic Diseases / EULAR & ACR
American College of Rheumatology: Five Things Physicians and Patients Should Question00.02.X · American College of Rheumatology
Assessment of antinuclear antibodies (ANA): National recommendations on behalf of the Croatian society of medical biochemistry and laboratory medicine21.03.X · Biochemia Medica / Croatian Society of Medical Biochemistry and Laboratory Medicine
Choosing Wisely's Treatments, Tests that Pediatric Rheumatologists and Patients Should Question00.04.X · American College of Rheumatology